Literature DB >> 8861033

Orchestration of the protective immune response to intracellular bacteria: Francisella tularensis as a model organism.

A Tärnvik1, M Ericsson, I Golovliov, G Sandström, A Sjöstedt.   

Abstract

Francisella tularensis is used as a model organism in studies of mechanisms behind the induction of a protective T-cell response in the mammalian host. Protective immunity is associated with a CD4 and CD8 T-cell response towards a mosaic of proteins of F. tularensis and due to HLA restriction, each individual selects her own mosaic. No single protein has so far been shown to be immunodominant. Only live F. tularensis affords effective host protection. Subcellular antigen preparations induce only a marginal protective response even when combined with potent adjuvants such as immunostimulating complexes (ISCOMs). In mice, intradermal injection of live F. tularensis but not of killed bacteria results in an early cytokine expression in the infected liver, including interleukin-12, tumor necrosis factor-alpha, and interferon-gamma. This cytokine response seems to be a prerequisite for effective priming of T cells to an array of proteins of F. tularensis to occur.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8861033     DOI: 10.1111/j.1574-695X.1996.tb00242.x

Source DB:  PubMed          Journal:  FEMS Immunol Med Microbiol        ISSN: 0928-8244


  12 in total

1.  Influence of the bcg locus on natural resistance to primary infection with the facultative intracellular bacterium Francisella tularensis in mice.

Authors:  H Kovárová; L Hernychová; M Hajdúch; M Sírová; A Macela
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

2.  Identification of T-cell epitopes in Francisella tularensis using an ordered protein array of serological targets.

Authors:  Michael D Valentino; Zachary J Maben; Lucinda L Hensley; Matthew D Woolard; Thomas H Kawula; Jeffrey A Frelinger; John G Frelinger
Journal:  Immunology       Date:  2011-01-07       Impact factor: 7.397

3.  Toll-like receptor 2 is required for control of pulmonary infection with Francisella tularensis.

Authors:  Meenakshi Malik; Chandra Shekhar Bakshi; Bikash Sahay; Aaloki Shah; Steven A Lotz; Timothy J Sellati
Journal:  Infect Immun       Date:  2006-06       Impact factor: 3.441

4.  Distinct roles of reactive nitrogen and oxygen species to control infection with the facultative intracellular bacterium Francisella tularensis.

Authors:  Helena Lindgren; Stephan Stenmark; Wangxue Chen; Arne Tärnvik; Anders Sjöstedt
Journal:  Infect Immun       Date:  2004-12       Impact factor: 3.441

5.  Cyclic di-GMP stimulates biofilm formation and inhibits virulence of Francisella novicida.

Authors:  Xhavit Zogaj; Geoff C Wyatt; Karl E Klose
Journal:  Infect Immun       Date:  2012-09-17       Impact factor: 3.441

6.  Neisseria meningitidis PorB, a Toll-like receptor 2 ligand, improves the capacity of Francisella tularensis lipopolysaccharide to protect mice against experimental tularemia.

Authors:  Damiana Chiavolini; Susan Weir; John R Murphy; Lee M Wetzler
Journal:  Clin Vaccine Immunol       Date:  2008-07-09

7.  Discrimination of human pathogenic subspecies of Francisella tularensis by using restriction fragment length polymorphism.

Authors:  Rebecca Thomas; Anders Johansson; Brendan Neeson; Karen Isherwood; Anders Sjöstedt; Jill Ellis; Richard W Titball
Journal:  J Clin Microbiol       Date:  2003-01       Impact factor: 5.948

Review 8.  Tularemia.

Authors:  Jill Ellis; Petra C F Oyston; Michael Green; Richard W Titball
Journal:  Clin Microbiol Rev       Date:  2002-10       Impact factor: 26.132

9.  Cytokine response in Balb/c mice infected with Francisella tularensis LVS and the Pohang isolate.

Authors:  Eun-Ju Kim; Sang-Hee Park; Young-Sill Choi; Soo-Kyoung Shim; Mi-Yeoun Park; Man Suck Park; Kyu-Jam Hwang
Journal:  J Vet Sci       Date:  2008-09       Impact factor: 1.672

Review 10.  Biofilms: an advancement in our understanding of Francisella species.

Authors:  Monique L van Hoek
Journal:  Virulence       Date:  2013-11-12       Impact factor: 5.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.